BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc.
Biocryst Pharmaceuticals Inc (BCRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 15,827,186 | $158,271,860 | 1.38% | |
| 2. | Deerfield Management James E. Flynn | 15,096,403 | $150,964,030 | +1% | 1.57% |
| 3. | Perceptive Advisors Joseph Edelman | 10,308,888 | $103,088,880 | +39% | 1.55% |
| 4. | Vestal Point Capital Ryan Wilder | 8,300,000 | $83,000,000 | +19% | 1.94% |
| 5. | Millennium Management Israel Englander | 3,394,729 | $33,947,290 | +1709% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.36 | 7,861 | $49,995.96 | 44,951 | 2024-05-30 | Filing | |
| $6.40 | 2,500 | $16,000.00 | 2,500 | 2024-05-24 | Filing | |
| $6.38 | 5,000 | $31,900.00 | 86,818 | 2024-05-20 | Filing | |
| $6.25 | 15,000 | $93,750.00 | 66,997 | 2024-05-20 | Filing | |
| $5.57 | 36,300 | $202,191.00 | 266,744 | 2024-05-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.97 | 11,180 | $100,284.60 | 31,252 | 2026-05-18 | Filing | |
| $9.54 | 62,500 | $596,250.00 | 400,703 | 2026-05-13 | Filing | |
| $10.11 | 49,933 | $504,822.63 | 65,352 | 2026-03-20 | Filing | |
| $9.15 | 150,000 | $1,372,500.00 | 400,703 | 2026-03-16 | Filing | |
| $7.65 | 21,773 | $166,563.45 | 398,751 | 2025-12-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 23,893,036 | $238,930,360 | 0% | |
| 2. | 15,191,098 | $151,910,980 | 0% | |
| 3. | 11,364,236 | $113,642,360 | 0% | |
| 4. | 11,139,158 | $111,391,580 | 0.01% | |
| 5. | 11,020,968 | $110,209,680 | 2.65% |
News See All
3 Best Stocks With 140%+ Upside to Buy This Week, According to Analysts
Analysts see major upside in some stocks this week, with three names showing more than 140% potential gains based on current price targets. While e...
Wall Street's 76 Biggest Earnings Winners
Latest data from financial data firm FactSet said an earnings per share growth of 15 percent or more is already considered an unusually strong result rather than a normal earnings outcome.
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?
Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on BCRX.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2026 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2026 Earnings Call Transcript May 6, 2026BioCryst Pharmaceuticals, Inc. misses on earnings expectations.
RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the best drug stocks to buy according to analysts. On April 7, RBC Capital lifted the price target on BioCryst Pharmaceuticals, Inc.
9 Best Drug Stocks to Buy According to Analysts
In this article, we will look at the 9 Best Drug Stocks to Buy According to Analysts.
10 Stocks Dominating Today's Market Action: Bloom, Vermilion and More
Ten stocks soared higher on Thursday, defying a wider market downturn, as investors loaded portfolios in companies seen as less vulnerable in the ongoing tensions in the Middle East.
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?
Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on BCRX.
BioCryst (BCRX) Soars 13% on Acquisition Buzz
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Worth Watching Right Now.
Hedge Fund Resource Center